<?xml version="1.0" encoding="utf-8"?>
<html madcap:lastblockdepth="4" madcap:lastheight="878" madcap:lastwidth="701" xmlns:madcap="http://www.madcapsoftware.com/Schemas/MadCap.xsd">
 <head>
 </head>
 <body>
  <h1>
   YM BioSciences Inc.
  </h1>
  <div style="display: none;">
   <table cellspacing="1" class="TableStyle-dnb_tablestyle_1" style="mc-table-style: url('../Resources/TableStyles/dnb_tablestyle_1.css');">
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <thead>
     <tr class="TableStyle-dnb_tablestyle_1-Head-Header1">
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       DUNS
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       Hoovers ID
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadD-Column1-Header1">
       Tier
      </th>
     </tr>
    </thead>
    <tbody>
     <tr class="TableStyle-dnb_tablestyle_1-Body-Body1">
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
        257322164
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
       119170
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyA-Column1-Body1" style="text-align: center;">
       3
      </td>
     </tr>
    </tbody>
   </table></div><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Synopsis.flsnp" /><p>
   YM BioSciences is a drug development company that focuses on treatments for blood and immune cell disorders. Its main candidate, CYT387, is in development for treating myelofibrosis, a rare blood disorder with limited treatment options. YM BioSciences was founded in 1994 with the backing of Canadian venture capital firm Covington Funds. In early 2013 it was acquired by
   <company id="15080">
    Gilead Sciences
   </company>
   for about $510 million; YM BioSciences was subsequently delisted and is now a wholly owned subsidiary of Gilead Sciences, itself a large HIV/AIDS drug maker. The acquisition adds a complementary clinical research program to treat blood cancers to Gilead Sciences' growing oncology portfolio.
  </p><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /></body>
</html>
